Intensive BP Reduction Linked to Higher CKD Incidence

In patients with hypertension and chronic kidney disease (CKD), more-intensive blood pressure–lowering therapy is associated with lower mortality risk, concludes a meta-analysis in JAMA Internal Medicine.

A systematic review identified 30 randomized clinical trials comparing more-intensive versus less-intensive blood pressure control in adults with stage 3 to 5 CKD. Meta-analysis comprised mortality data from 18 trials including 15,924 participants with CKD, 1293 of whom died. Thirteen trials had two defined blood pressure targets; five studies compared blood pressure-lowering therapy with no treatment or placebo.

At baseline, systolic blood pressure was similar between groups: mean 148 mm Hg. Mean reductions in systolic blood pressure were 16 mm Hg in patients assigned to the more-intensive interventions versus 8 mm Hg in the less-intensive group.

Mortality was 7.8% in the more-intensive group versus 8.4% in the less-intensive group. The reduction in all-cause mortality was significant: odds ratio 0.86. There was no evidence of heterogeneity, and the results were similar in subgroup analyses, including exclusion of SPRINT.

This meta-analysis suggests a 14% reduction in all-cause mortality with more-intensive blood pressure-lowering therapy among patients with stage 3 to 5 CKD. The mortality benefit appeared larger in trials with greater reductions in systolic blood pressure, although this was not significant. While emphasizing the need for further studies and safety monitoring, the investigators conclude, “[T]hese data support that the net benefits may outweigh the net harms of more intensive BP lowering in persons with CKD” [Malhotra R, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med 2017; DOI:10.1001/jamainternmed.2017.4377].

October/November 2017 (Vol. 9, Number 10 & 11)